Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M

LIFECORE BIOMEDICAL, INC. DE

2025-FY EPS reported -$0.09 revenue$8,665,000

Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.
FY2025 revenue $128.9M (+0.5% YoY); net loss $38.7M vs $12.0M income; adj. EBITDA $19.5M vs $20.2M.
Signed nine new customer programs in FY2025; post-quarter added GLP-1 obesity therapy and Phase 2 dermatology programs.
Transition period (May-Dec 2025) guidance: revenue $74-76M; adj. EBITDA $12-14M; net loss $19.8-17.8M.
Moving fiscal year to calendar year-end Dec 31, 2025; new ERP system planned for Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.